No excess mortality risk for 10-­years survivors after high dose therapy with autologous stem cell transplantation (HDT‐ASCT) for relapsed/refractory Hodgkin's lymphoma (HL)

Autor: Smeland, Knut Bjøro, Kiserud, Cecilie E, Loge, Jon Håvard, Kolstad, Arne, Fosså, Alexander, Fagerli, Unn Merete, Falk, Ragnhild Sørum, Lauritzsen, Grete F, Oystein Fluge, Maisenhølder, Martin, Kvaløy, Stein, Holte, Harald
Jazyk: angličtina
Rok vydání: 2014
DOI: 10.13140/2.1.1727.8723
Databáze: OpenAIRE